Freeline_Logo_Red_RGB.jpg
Freeline presents new Haemophilia B data at the International Society on Thrombosis and Haemostasis (ISTH) 2020 Meeting
July 13, 2020 11:45 ET | Freeline Therapeutics
- Updated FLT180a data in the B-AMAZE study in severe Haemophilia B patients demonstrated the potential for sustained normal FIX activity levels - - Additional data were presented in 5 poster...
THUMB_1740-12_Silhouette Vertical Full Color.png
Abeona Therapeutics Announces Appointment of Michael Amoroso as Chief Commercial Officer
July 09, 2020 07:30 ET | Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, July 09, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced the appointment of Michael...
THUMB_1740-12_Silhouette Vertical Full Color.png
Abeona Therapeutics Reinitiates Enrollment in EB-101 Pivotal Phase 3 VIITAL™ Study in RDEB after COVID-19 Related Pause and Announces Progress in Patient Enrollment in MPS III Studies
July 08, 2020 07:30 ET | Abeona Therapeutics Inc.
NEW YORK and CLEVELAND, July 08, 2020 (GLOBE NEWSWIRE) -- Abeona Therapeutics Inc. (Nasdaq: ABEO), a fully-integrated leader in gene and cell therapy, today announced recent updates on its clinical...
Freeline_Logo_Red_RGB.jpg
Freeline Announces Additional Financing Plans
June 30, 2020 02:00 ET | Freeline Logo
LONDON, June 30, 2020 (GLOBE NEWSWIRE) -- Freeline, a biotechnology company focused on developing curative gene therapies for chronic systemic diseases, today announced that it expects to consider...
Freeline_Logo_Red_RGB.jpg
Freeline Closes $120 Million Series C Financing Round
June 30, 2020 02:00 ET | Freeline Logo
LONDON, June 30, 2020 (GLOBE NEWSWIRE) -- Freeline, a biotechnology company focused on developing curative gene therapies for chronic systemic diseases, today announced the closing of a $120 million...
Freeline_Logo_Red_RGB.jpg
Freeline announces acceptance of Late Breaking Abstract at the International Society on Thrombosis and Haemostasis (ISTH) 2020 Meeting
June 29, 2020 09:00 ET | Freeline Logo
- Updated data will be presented in an oral presentation on the efficacy and safety of AAV gene therapy FL180a in the B-AMAZE study in severe haemophilia B patients - - Additional data will be...
EHang NasdaqListed Logo.png
EHang Reports First Quarter 2020 Unaudited Financial Results
May 29, 2020 06:00 ET | EHang Holdings Limited
-  Solid Results Despite Pandemic Challenges-  YoY Growth in Revenue, Gross Margin and Air Mobility Solutions-  Global Progress: U.S., Spain, Norway and China-  Pandemic Reveals New Applications in...
EHang Holdings Limited Announced Appointment of Independent Director
EHang Holdings Limited Announced Appointment of Independent Director
May 28, 2020 08:30 ET | EHang Holdings Limited
GUANGZHOU, China, May 28, 2020 (GLOBE NEWSWIRE) -- EHang Holdings Limited (Nasdaq: EH) (“EHang” or the “Company”), the world's leading autonomous aerial vehicle (“AAV”) technology platform company,...
EHang NasdaqListed Logo.png
EHang to Participate in Upcoming Investor Conferences
May 25, 2020 08:30 ET | EHang Holdings Limited
GUANGZHOU, China, May 25, 2020 (GLOBE NEWSWIRE) -- EHang Holdings Limited (Nasdaq: EH) (“EHang” or the “Company”), the world's leading autonomous aerial vehicle (“AAV”) technology platform company,...
EHang NasdaqListed Logo.png
EHang to Report First Quarter 2020 Unaudited Financial Results on May 29, 2020
May 21, 2020 08:30 ET | EHang Holdings Limited
GUANGZHOU, China, May 21, 2020 (GLOBE NEWSWIRE) -- EHang Holdings Limited (“EHang” or the “Company” ) (Nasdaq: EH), the world’s leading autonomous aerial vehicle (AAV) technology platform company,...